Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis
Objective To evaluate the utility of Golgi protein 73 (GP73) in the diagnosis of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) staging. Methods Ninety-one patients with non-alcoholic fatty liver disease (NAFLD) were allocated to NAFL (n = 46) and NASH (n = 45) groups according to th...
Guardado en:
Autores principales: | Yadi Li, Yan Yang, Yufang Li, Ping Zhang, Gaiying Ge, Jing Jin, Ting Du, Maiyan Ma, Li Na, Lu Ding, Huiping Sheng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60cd23d260914424a575ae045b443a29 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis
por: Arthur C. Sletten, et al.
Publicado: (2021) -
Statins in Non-alcoholic Steatohepatitis
por: Jose D. Torres-Peña, et al.
Publicado: (2021) -
GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity
por: Yumeng Peng, et al.
Publicado: (2021) -
Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system
por: Tomasz Kostrzewski, et al.
Publicado: (2021) -
Author Correction: Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis
por: Arthur C. Sletten, et al.
Publicado: (2021)